Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors

2017 ◽  
Vol 84 ◽  
pp. 9-17 ◽  
Author(s):  
M. Bandak ◽  
N. Jørgensen ◽  
A. Juul ◽  
J. Lauritsen ◽  
P.S. Oturai ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Systemic Inflammation ◽  
Leydig Cell ◽  
Cell Dysfunction ◽  
Testicular Cancer Survivors

Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction

2019 ◽  
Vol 17 (1) ◽  
pp. e65-e71
Author(s):  
Julie Wang Skøtt ◽  
Jakob Lauritsen ◽  
Michael Kreiberg ◽  
Gedske Daugaard ◽  
Mikkel Bandak
Keyword(s):  
Quality Of Life ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Leydig Cell ◽  
Cell Dysfunction ◽  
Testicular Cancer Survivors

scholarly journals Quantification of the Leydig cell compartment in testicular biopsies and association with biochemical Leydig cell dysfunction in testicular cancer survivors

Andrology ◽  
2018 ◽  
Vol 6 (5) ◽  
pp. 748-755 ◽  
Author(s):  
M. G. Tarsitano ◽  
M. Bandak ◽  
N. Jørgensen ◽  
N. E. Skakkebaek ◽  
A. Juul ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Leydig Cell ◽  
Cell Compartment ◽  
Cell Dysfunction ◽  
Testicular Cancer Survivors

Metabolic syndrome in long-term testicular cancer survivors

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4576-4576
Author(s):  
H. Sagstuen ◽  
N. Aass ◽  
S. D. Fosså ◽  
O. Dahl ◽  
O. Klepp ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Testicular Cancer Survivors

A study of coping in long-term testicular cancer survivors

2010 ◽  
Vol 15 (2) ◽  
pp. 146-158 ◽  
Author(s):  
Robert Rutskij ◽  
Torfinn Gaarden ◽  
Roy Bremnes ◽  
Olav Dahl ◽  
Arnstein Finset ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Testicular Cancer Survivors

Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer Survivors

2007 ◽  
Vol 25 (6) ◽  
pp. 708-714 ◽  
Author(s):  
Jan Oldenburg ◽  
Sigrid M. Kraggerud ◽  
Milada Cvancarova ◽  
Ragnhild A. Lothe ◽  
Sophie D. Fossa
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Hearing Impairment ◽  
Glutathione S Transferase ◽  
Functional Polymorphisms ◽  
Hearing Ability ◽  
Interindividual Variations ◽  
Glutathione S Transferases ◽  
Testicular Cancer Survivors

Purpose Cisplatin, a cornerstone of combination chemotherapy in the treatment of testicular cancer, induces hearing impairment with considerable interindividual variations. These differences might be a result of functional polymorphisms in cisplatin-detoxifying enzymes like glutathione S-transferases (GSTs). Patients and Methods We identified 173 cisplatin-treated testicular cancer survivors (TCSs) who had participated in a long-term survey that included audiometric testing and lymphocyte sampling. The hearing decibel thresholds at 4,000 Hz were categorized into leveled scales by normative decibel percentiles. Known functional polymorphisms (positive or negative) in GSTT1 and GSTM1 and codon 105 A/G (Ile/Val) in GSTP1 were analyzed by multiplex polymerase chain reaction, followed by restriction enzyme cutting, and separated by gel electrophoresis. Results The risk of having an inferior audiometric result was more than four times higher in TCSs with 105Ile/105Ile-GSTP1 or 105Val/105Ile-GSTP1 compared with 105Val/105Val-GSTP1 (odds ratio [OR] = 4.21; 95% CI, 1.99 to 8.88; P < .001 when modeled by ordinal logistic regression [OLR]). GSTM1 positivity was detrimental for hearing ability. Two combined genotypes were associated with hearing ability. The presence of pattern 1 (GSTT1 positive, GSTM1 positive, and 105Ile/105Ile-GSTP1) was associated with hearing impairment (OR = 2.76; 95% CI, 1.35 to 5.64; P = .005, OLR). TCSs with pattern 2 (GSTT1 positive, GSTM1 positive, and 105Val/105Val-GSTP1) had better hearing ability than TCSs without this pattern (OR = 5.35; 95% CI, 2.25 to 12.76; P < .001, OLR). Conclusion The presence of both alleles of 105Val-GSTP1 offered protection against cisplatin-induced hearing impairment. Two genotype patterns with good and poor protection against cisplatin-induced ototoxicity were identified.

scholarly journals Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors

2015 ◽  
Vol 26 (10) ◽  
pp. 2133-2140 ◽  
Author(s):  
M. Sprauten ◽  
H.S. Haugnes ◽  
M. Brydøy ◽  
C. Kiserud ◽  
T. Tandstad ◽  
...  
Keyword(s):  
Risk Factors ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Chronic Fatigue ◽  
Long Term Follow Up ◽  
Testicular Cancer Survivors

scholarly journals Long-Term Follow Up of the Erectile Function of Testicular Cancer Survivors

2019 ◽  
Vol 10 ◽  
Author(s):  
Francesco Pallotti ◽  
Alessandra Petrozzi ◽  
Francesco Cargnelutti ◽  
Antonio Francesco Radicioni ◽  
Andrea Lenzi ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Erectile Function ◽  
Long Term Follow Up ◽  
Testicular Cancer Survivors
Sign in / Sign up

Export Citation Format

Share Document